December 3, 2020


AZ’s Muddy Result, Regeneron Cocktail OK’d, and Biogen, Sage Bet Big on Depression

Take two weeks between Frontpoints columns, and a lot of stuff happens. On Monday Nov. 23, AstraZeneca presented a muddy picture from its Phase III clinical trial with a COVID-19 vaccine developed on adenovirus technology with Oxford University. It’s either delivering 90 percent efficacy or 62 percent efficacy, depending on the dose. So it’s either great or good, but we’re...
Read More